Beilu Pharma(SZ:300016) Zheng Quan Shi Bao·2025-08-25 15:11Core Viewpoint - North Lu Pharmaceutical (300016) reported a strong performance in the first half of 2025, with significant growth in revenue and net profit, driven by stable growth in chemical drugs, traditional Chinese medicine, and raw materials [1][2][3]. Revenue and Profit Growth - The company achieved operating revenue of 584.21 million yuan, a year-on-year increase of 23.27% [1] - Net profit attributable to shareholders reached 29.97 million yuan, up 53.35% year-on-year [1] - The net profit after deducting non-recurring gains and losses was 29.74 million yuan, reflecting a 55.58% increase year-on-year [1] - Both revenue and profit showed growth momentum in the second quarter compared to the first quarter [1] Product Performance - Contrast agents saw a sales revenue of 338.88 million yuan, growing by 21.11% year-on-year [2] - The sales revenue of hypoglycemic products was 68.22 million yuan, with a growth of 2.22% [2] - The chemical drug segment generated a total sales revenue of 407.09 million yuan, an increase of 17.47% year-on-year [2] - Traditional Chinese medicine (TCM) preparations achieved sales revenue of 118.19 million yuan, marking a growth of 32.84% [4] Strategic Developments - The company has expanded its TCM product matrix significantly, now offering 59 varieties, including 21 that are currently marketed [3][10] - The "Nine Flavors Heart-Calming Granules" is recognized as the first pure TCM preparation approved for treating generalized anxiety disorder, establishing the company as a leader in this niche [3] - The company’s raw material drug segment reported sales revenue of 53.40 million yuan, with a year-on-year increase of 45.81% [6] International Market Expansion - The company is actively expanding into overseas markets, achieving overseas revenue of 74.29 million yuan, a growth of 30.41% [8] - The company has received approvals for its contrast agents and iodine contrast raw materials in multiple countries, facilitating further international market access [7] Research and Development - R&D investment reached 39.03 million yuan, a 10.09% increase compared to the previous year [9] - The company has 34 projects in the pipeline, including 16 under review and 18 newly initiated [9] - The company continues to enhance its product pipeline in the contrast agent field, with several raw materials approved for market [9] Financial Management - The company completed the early redemption of its convertible bonds on July 14, 2025, significantly reducing financial pressure [11] - The completion of this redemption is expected to improve the company's capital structure and lower financial costs [11]